risperidone has been researched along with Dyslipidemias in 13 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Dyslipidemias: Abnormalities in the serum levels of LIPIDS, including overproduction or deficiency. Abnormal serum lipid profiles may include high total CHOLESTEROL, high TRIGLYCERIDES, low HIGH DENSITY LIPOPROTEIN CHOLESTEROL, and elevated LOW DENSITY LIPOPROTEIN CHOLESTEROL.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Risperidone use in children and adolescents is associated with the development of metabolic disorders including increased accumulation of body fat, dyslipidemia, and glucose and insulin metabolism dysregulation." | 7.96 | Exercise intervention for preventing risperidone-induced dyslipidemia and gluco-metabolic disorders in female juvenile rats. ( Deng, C; Han, M; Sylvester, E; Yi, W, 2020) |
| "Risperidone use in children and adolescents is associated with the development of metabolic disorders including increased accumulation of body fat, dyslipidemia, and glucose and insulin metabolism dysregulation." | 3.96 | Exercise intervention for preventing risperidone-induced dyslipidemia and gluco-metabolic disorders in female juvenile rats. ( Deng, C; Han, M; Sylvester, E; Yi, W, 2020) |
| "Children treated with risperidone or quetiapine are at a significant risk for developing obesity, elevated waist circumference, and dyslipidemia during 12 months of treatment." | 3.81 | Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study. ( Davidson, J; Nguyen, D; Panagiotopoulos, C; Ronsley, R, 2015) |
| "RLAI and OP show good short- and long-term safety when treating patients with schizophrenia, with uncommon discontinuation due to adverse effects." | 2.46 | Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. ( Cañas, F; Möller, HJ, 2010) |
| "Data for 60,162 subjects with type 1 diabetes up to the age of 25 years registered in the nationwide German/Austrian Diabetes Survey were included in the analysis." | 1.42 | Comparison of glycemic and metabolic control in youth with type 1 diabetes with and without antipsychotic medication: analysis from the nationwide German/Austrian Diabetes Survey (DPV). ( Bartus, B; Bollow, E; Galler, A; Haberland, H; Holl, RW; Meusers, M; Näke, A; Schober, E, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (46.15) | 29.6817 |
| 2010's | 6 (46.15) | 24.3611 |
| 2020's | 1 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Sylvester, E | 1 |
| Yi, W | 1 |
| Han, M | 1 |
| Deng, C | 1 |
| Pisano, S | 1 |
| Gritti, A | 1 |
| Catone, G | 1 |
| Pascotto, A | 1 |
| Galler, A | 1 |
| Bollow, E | 1 |
| Meusers, M | 1 |
| Bartus, B | 1 |
| Näke, A | 1 |
| Haberland, H | 1 |
| Schober, E | 1 |
| Holl, RW | 1 |
| Bonaccorso, S | 1 |
| Sodhi, M | 1 |
| Li, J | 1 |
| Bobo, WV | 1 |
| Chen, Y | 1 |
| Tumuklu, M | 1 |
| Theleritis, C | 1 |
| Jayathilake, K | 1 |
| Meltzer, HY | 1 |
| Ronsley, R | 1 |
| Nguyen, D | 1 |
| Davidson, J | 1 |
| Panagiotopoulos, C | 1 |
| Lee, E | 1 |
| Leung, CM | 1 |
| Duncan, EJ | 1 |
| Woolson, SL | 1 |
| Hamer, RM | 1 |
| Dunlop, BW | 1 |
| Cañas, F | 1 |
| Möller, HJ | 1 |
| Adeneye, AA | 1 |
| Agbaje, EO | 1 |
| Olagunju, JA | 1 |
| Lin, SK | 1 |
| Chen, CK | 1 |
| Wooten, J | 1 |
| Perlis, RH | 1 |
| Perez-Iglesias, R | 1 |
| Crespo-Facorro, B | 1 |
| Amado, JA | 1 |
| Garcia-Unzueta, MT | 1 |
| Ramirez-Bonilla, ML | 1 |
| Gonzalez-Blanch, C | 1 |
| Martinez-Garcia, O | 1 |
| Vazquez-Barquero, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)[NCT04395326] | 120 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for risperidone and Dyslipidemias
| Article | Year |
|---|---|
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.
Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Dyslipidem | 2010 |
Metabolic effects of the atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepine | 2007 |
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Bipolar Disorder; Diabete | 2007 |
2 trials available for risperidone and Dyslipidemias
| Article | Year |
|---|---|
The brain-derived neurotrophic factor (BDNF) Val66Met polymorphism is associated with increased body mass index and insulin resistance measures in bipolar disorder and schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Body Mass In | 2015 |
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
Topics: Adolescent; Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass In | 2007 |
8 other studies available for risperidone and Dyslipidemias
| Article | Year |
|---|---|
Exercise intervention for preventing risperidone-induced dyslipidemia and gluco-metabolic disorders in female juvenile rats.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Body Mass Index; Dyslipidemias; Female; Glucose Tolera | 2020 |
Antipsychotic-induced dyslipidemia treated with omega 3 fatty acid supplement in an 11-year-old psychotic child: a 1-year follow-up.
Topics: Antipsychotic Agents; Child; Dietary Supplements; Dyslipidemias; Fatty Acids, Omega-3; Follow-Up Stu | 2013 |
Comparison of glycemic and metabolic control in youth with type 1 diabetes with and without antipsychotic medication: analysis from the nationwide German/Austrian Diabetes Survey (DPV).
Topics: Adolescent; Adult; Albuminuria; Antipsychotic Agents; Blood Glucose; Body Mass Index; Diabetes Compl | 2015 |
Increased Risk of Obesity and Metabolic Dysregulation Following 12 Months of Second-Generation Antipsychotic Treatment in Children: A Prospective Cohort Study.
Topics: Adolescent; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Behavior Disor | 2015 |
Atypical antipsychotics and metabolic outcomes in Chinese patients: a comparison of olanzapine and risperidone.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; China; Cross-Sectional Studies; Dose-Response Re | 2008 |
Risk of lipid abnormality with haloperidol, olanzapine, quetiapine, and risperidone in a Veterans Affairs population.
Topics: Antipsychotic Agents; Benzodiazepines; Case-Control Studies; Dibenzothiazepines; Dyslipidemias; Fema | 2009 |
Metformin: an effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Disease Models, Animal; Dyslipidemias; Glyburide; Huma | 2011 |
Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dyslipidemias; Female; Humans; Hyperprolactinemia; Obesit | 2006 |